News of Note—Lonza adds API lines for AstraZeneca; Biocon gets EU OK

stock market prices
(Pixabay)

> Lonza is adding two lines at its site in Visp, Switzerland, for production of highly potent APIs as part of a supply deal with AstraZeneca. Release

> Indian biosimilar maker Biocon says its biologics drug product facility and its drug substance facility in Bengaluru were approved by the European Medicines Agency following a March inspection. Release

> AptarGroup in Crystal Lake, Illinois, is spending about $50 million to buy pharmaceutical services companies Nanopharm and Gateway Analytical to expand its offerings to the biopharma industry. Release

> The Medicines and Healthcare products Regulatory Agency in the U.K. is recalling two batches of 500 mg paracetamol tablets produced by M&A Pharmachem because of discoloration caused by fungi. Stor

Suggested Articles

GBA offers Brexit escape, Merck and Just - Evotech to share production space, GSK ointment line in Bangladesh may reopen and more news of note.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.